EP Patent

EP4450070A1 — Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Assigned to Neurocrine Biosciences Inc · Expires 2024-10-23 · 2y expired

What this patent protects

CRF, receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

USPTO Abstract

CRF, receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

Drugs covered by this patent

Patent Metadata

Patent number
EP4450070A1
Jurisdiction
EP
Classification
—
Expires
2024-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.